UF-KURE19

UF-KURE19 is a second-generation 4-1BB CAR-T cell therapy manufactured in less than one day using a simplified workflow that omits the need for T-cell isolation and expansion. This ultra-fast manufacturing platform significantly reduces production time compared to traditional CAR-T therapies, which typically require 7-14 days. The therapy targets CD19-positive cells and has shown high efficacy and tolerability in clinical trials for relapsed/refractory non-Hodgkin lymphoma, with 80% of treated patients achieving complete responses and low toxicity rates. Preclinical data demonstrated that UF-KURE19 CAR-T cells exhibited markedly enhanced in vivo proliferation compared to conventionally manufactured products.

Other names

UF-KURE19 CAR-T cellsUF-KURE-19 CAR-T cellsUF-KURE 19 CAR-T cellsautologous anti-CD19 CAR-expressing T lymphocytes UF-KURE19